What is HC Wainwright’s Forecast for ADAP Q1 Earnings?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnology company will post earnings per share of ($0.18) for the quarter. HC Wainwright currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

ADAP has been the subject of a number of other research reports. StockNews.com downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday. Guggenheim dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP opened at $0.59 on Friday. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09. The stock has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $1.03. The stock has a market capitalization of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. increased its holdings in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares in the last quarter. Long Focus Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after purchasing an additional 394,566 shares during the last quarter. FMR LLC lifted its stake in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after buying an additional 50,419 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 98,581 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.